Our clinical partners have requested we take into account the historic resistance profile of the patient, even if some mutations were not currently present due to lack of drug pressure. We are proud to announce this functionality when more and more governments and insurance agencies are recognizing the value of genotype testing and reimbursing for its cost.
Topsfield, MA (PRWEB) March 30, 2005
ABL, SA (A Luxembourg Company) with TherapyEdge Inc. (Durham, NC) today announced it had signed a license agreement to use the Stanford University HIVdb resistance interpretation algorithm in their ViroScorer Report.
The ViroScorer HIV report is part of the ViroScore Suite which provides decision support to HIV doctors by helping them select the best therapy for an HIV patient based on the past and current resistance to HIV drugs. The report has picked up a lot of support from opinion leaders in HIV clinical research as it offers a global interpretation based on research from six leading research centers across the world.
Jean-Claude Schmit, a leading HIV resistance researcher in Europe and the Clinical Director of the Virology Lab at Centre Hospital de Luxembourg, the author of one of the European algorithms in the report, has praised the ABL team for broadening the product line. "The ViroScore Test and the Suite of tools for individual patient treatment and longitudinal research are now unmatched in the Field. Stanford has some of the best researchers in the world and a large pool of genetic sequence data to create and refine their algorithm."
The Stanford Algorithm will round out the resistance interpretation for ABL customers across the globe and in particular in the US where ABL is expanding. Chairman of the board of ABL, Arsene Kronshagen said that, "this algorithm will help us expand in the Americas because it is widely accepted as the standard for HIV resistance interpretation in the region."
ABL sells the resistance interpretation platform to diagnostic companies, HIV researchers and individual physicians treating HIV. The ViroScore Suite of tools includes an enterprise class database for the storage of genetic sequence data, analysis tools for reporting on the relationships between clinical outcomes and virus mutations, phylogenetic analysis of sequence groups and numerous tools to assist the physicians and researchers in optimizing the use of complex genetic data.
ABL will also use the Stanford algorithm in the "ViroScore-PLUS" Report which provides resistance interpretation based on the patients current and past resistance history. Ronan Boulme, VP of Research and Development added, "Our clinical partners have requested we take into account the historic resistance profile of the patient, even if some mutations were not currently present due to lack of drug pressure. We are proud to announce this functionality when more and more governments and insurance agencies are recognizing the value of genotype testing and reimbursing for its cost."
ABL includes the Stanford Algorithm in version 6.2 of the ViroScore Suite released March 28th and is offering upgrades to existing customers in over 36 countries.
To license the ABL products, to learn about our company or to start a research partnership, please visit http://www.ablsa.com. ABL is currently seeking a distribution partner for their technologies in the North American region.
# # #